Background: Mohs micrographic surgery examines all margins of the resected sample and has a 99% cure rate. However, many nonmelanoma skin cancers (NMSCs) are not readily amenable to Mohs micrographic surgery. This defines an unmet clinical need to assess the completeness of non-Mohs micrographic surgery resections during surgery to prevent re-excision/recurrence.
Nonmelanoma skin cancer (NMSC) is the most common form of human cancer with approximately 3.5 million cases diagnosed in the United States in 2006 and approximately 4 million diagnosed each year hence. 1, 2 Approximately 80% of all NMSC are basal cell carcinomas (BCC) with most of the remaining being squamous cell carcinomas (SCC). 3 Several approaches to ensure complete removal of diseased tissue with minimal resection of normal tissue have been developed, including Mohs micrographic surgery (MMS) 4, 5 that checks margins during surgery and has the highest cure rate of all approaches (99%). However, conventional or non-MMS resection is the most common surgical approach for skin cancers representing approximately 75% of surgical procedures for BCC and SCC 1 and has much lower cure rates than MMS.
Well-differentiated SCC cure rates approach 81% using non-MMS procedures but decreases to 46% for poorly differentiated lesions. 6 Resections of BCC fare slightly better with approximately 93% cure rates. 7 Because rates are related to the size of margins that the dermatologist removes, conventional resections generally result in larger resections of normal tissue to ensure clear margins, which are determined by conventional pathology several days after the surgery. 8, 9 Here we describe an easily interpretable methodology that could be cost-effectively deployed and rapidly executed to enable surgeons to better assess peripheral surgical margins, thus reducing the amount of normal tissue resected during conventional NMSC excisions.
The study presented exploits molecular imaging technology 10, 11 to target overexpressed skin cancer-associated cathepsin proteases. [12] [13] [14] [15] [16] The technique uses a cysteine cathepsin selective class of near-infrared fluorescent quenched activity-based probes (QABPs) 17 effective for imaging tumorexpressed cathepsins, in vitro and in vivo, [18] [19] [20] [21] [22] which are hydrophobic and readily penetrate the skin. Interaction of QABPs with target proteases results in de-quenching and production of a fluorescent signal. Here, GB119 is used to target cancer cysteine cathepsin enzymes to discriminate NMSC from normal-appearing skin ex vivo creating a 2-dimensional (2D) fluorescent map for each sample. Specifically, ex vivo topical administration of this probe is used to develop a standardized method to differentiate cancer from normal-appearing skin in excised human skin cancer specimens.
METHODS

Collection of human skin specimens
This study was approved by the University Hospitals Case Medical Center Institutional Review Board (protocol #12-05-17). Discarded skin tissues containing previously diagnosed BCC or SCC were taken during debulking for MMS (eTable I) for this prospective case series. All BCC/SCC debulk specimens greater than or equal to 1 3 1 cm were processed, imaged, and analyzed.
Ex vivo imaging of human skin specimens Freshly removed debulk specimens were covered with saline-soaked gauze and delivered to the laboratory 90 to 120 minutes after surgery. Samples were rinsed with saline, blotted dry with gauze, followed by baseline imaging (0 minutes). Probe GB119 (10 mol/L in dimethyl sulfoxide) (Sigma-Aldrich, St Louis, MO) was applied to the dermal side. After 5 minutes, excess probe was rinsed from the sample with saline and the dried sample was imaged in the Maestro imaging system (PerkinElmer, Waltham, MA) with a near-infrared filter set. Two sectioning approaches were used (Graphical abstract, Step 4). In the breadloaf section, ink was used to mark the location of fluorescence before signals sectioning.
Analysis of Cy5-fluorescence
Fluorescence was measured and pseudo-color images were derived using Maestro and supplied software 3.0.1.2 (PerkinElmer). Levels of autofluorescence (0 minutes) were subtracted from fluorescence at 5 minutes with GB119 and remaining signal intensity was pseudo-colored. Signal was mapped onto the surface of the samples and inked in some cases. Samples were immersed in optimal cutting temperature compound, snap-frozen, and kept at À808C for further study.
Histologic and immunofluorescent analysis of human skin samples
Frozen blocks were sectioned (10 m) in a breadloaf manner at À308C (Leica-CM3050S).
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The cryosections were then fixed and stained with hematoxylin-eosin (H&E). For en face sectioning specimens were not inked and the entire frozen blocks were sectioned from dermal side toward epidermal side. Immunohistochemistry (IHC) for activated GB119 and cathepsin expression was performed on adjacent 10-m sections for detection of unquenched/activated GB119 and cathepsineL or eB, as described in Walker et al. 11 Tissue nuclei were contrasted with Fluoro-Gel-II with 49,6-diamidino-2-phenylindole (Electron Microscopy Sciences, Hatfield, PA).
Microscopy
Fluorescent images were viewed with a Leica-DM4000B microscope (bandpass = 480/527, anticathepsin-L and -B and bandpass = 560/645, antiCy5) and analyzed with QCapturePro-7 software (Leica Microsystems, Buffalo Grove, IL). An Olympus-VS120/S5 (Olympus Life Science, Tokyo, Japan) versatile microscope-based scanner was used to generate histologic images larger than a single field of view. Overlays between H&E and Cy5-fluorescent images were done manually. Technically validated results were included in the analyses and no data were excluded as outliers. H&E examination of BCC/ SCC slides was performed by 2 pathologists without knowledge of Cy5-fluorescent imaging or other information. All annotations of the position of BCC/ SCC and normal tissue were made by pathologists directly on the histologic slides via marking pens.
Sensitivity and specificity analysis
Sensitivity and specificity were estimated as binomial proportions and exact 95% confidence intervals were calculated. The data set consisted of 55 samples from 54 patients (35 BCC and 20 SCC). A total of 72 histology sections (slides), containing 137 regions of interest were examined. Ninety regions of interest having tumor and 47 marked as having no tumor were treated as independent observations in a perspot analysis; these sample sizes allowed estimation of overall sensitivity and specificity within 6 0.06 and 0.09, respectively, using 95% confidence intervals when true sensitivity or specificity equaled 0.90. The subtypes of all available samples are reported in eTable I.
RESULTS
QABP fluorescence discriminates between NMSC and normal tissue ex vivo First we determined that normal-appearing human skin does not activate our imaging probe, GB119, after topical application (Fig 1, A) . After topical application of GB119 to the nonepidermal surface of a sample containing either BCC or SCC there was significant probe activation resulting in increased fluorescence viewed en face (Fig 1, B and C ) . Pathological correlation of the location of cancer and fluorescent signal in conventional breadloaf sections taken from these specimens showed a good association and clear demarcation between normal and cancerous tissues (lower panels Fig 1, B and C ) .
The sensitivity and specificity of the probe for detecting NMSC in BCC samples were 100% and 87%, respectively (Table I) . Similarly, using SCC samples only, the sensitivity and specificity were 97% and 92%, respectively (Table I ). There were no significant differences in probe activation among the subtypes of BCC and SCC and signal strength was significantly higher in NMSC versus normal-appearing skin (eFig 1 and eTable I).
Presence of activated GB119 correlates with the expression of cathepsin-L in and around skin cancer
To further validate and characterize the relationship of probe activation with its cognate enzyme, IHC analysis was performed for cathepsin proteases (Fig 2) . Breadloaf sections were prepared from normal-appearing, BCC, and SCC skin samples that were treated with GB119, and then underwent H&E staining and IHC for cathepsins and the activated probe. The results confirm that normal tissue expresses low levels of cathepsins and shows little to no activation of the probe. Within cancer lesions, cathepsin expression was elevated and correlated to probe activation, with the highest probe signal and expression of cathepsins occurring at the edge of the cancer nests both in BCC and SCC (Fig 2) . Controls confirmed the specificity of the assay (eFig 2 in the Supplement). These studies also demonstrated that probe activation occurred in the thickest sample analyzed, approximately 2.5 mm (eFig 3 and eTable I).
Fluorescence imaging defines the cancer diameter at different depths within the skin cancer lesion
Next, 2D epifluorescence imaging of flat skin samples was correlated to the location of cancer within different depths of the skin specimens. Fig 3 shows a BCC skin sample topically treated with GB119, imaged (Fig 3, A) , frozen, and en face sectioned followed by histology and IHC to identify the location of activated probe and NMSC. Sections from 4 different depths from the dermal site of application were assessed by blinded pathologists (up to 0.8 mm [Fig 3 , B] and up to 2.5 mm [eFig 3]) and bolded contour lines representing the cancer (black/purple) and inflammation (red) perimeters at each depth were superimposed on the 2D fluorescence image of the corresponding skin sample (Fig 3, C ) , the larger distances representing the farthest distance from the dermal site of probe application. These data show the heterogeneous location of the edge of cancerous tissue at different depths within the tissue specimens. The inflammatory milieu of cancer was found both inside and at the edge of the cancer lesions at different depths. As is evident in both Fig 3, B and C, the combination of the histology contour maps depicting cancer and its inflammatory milieu completely outline the fluorescence maps, demonstrating that the fluorescence signal, which comes from different depths within the lesion, accurately marks the perimeter of the cancerous lesion for BCC samples and potentially could be used to inform the location of peripheral margins for conventionally resected skin cancer. Similar results were obtained for SCC skin samples where sections at the depths up to 1.9 mm were analyzed by pathologists (eFig 4 and eTable I).
To determine the exact correlation of fluorescence signal within cancer borders, the data from Fig 4, A) . These regions were then further analyzed to achieve a more detailed correlation of the location of cancer, cathepsin-L, and activated GB119 probe. Fig 4, B-D, show that there was a high degree of correlation between the presence of fluorescence and the location of BCC lesions and normalappearing skin. Similar results were obtained for SCC samples, and inflammation associated with the sample was also observed in the regions with the highest level of GB119 activation and demonstrated cathepsin B is also associated with probe activation (eFigs 4, 5, and 6). The effect of blood clots affecting signal was demonstrated in eFig 7.
DISCUSSION
The results of this study suggest a potentially promising approach to the surgical resection of NMSC, showing that the QABP GB119 topically applied to tissue after excision can discriminate between normal-appearing skin and either BCC or SCC tissues within minutes. Following the breadloafing procedure outlined in the graphical abstract, these studies used 55 skin cancer specimens to demonstrate 90% or higher overall sensitivity and specificity for detecting BCC/SCC cancer lesions in a background of normal human tissue (Table I and Fig  1) . Further, subtypes of BCC (nodular, micronodular, superficial, and infiltrative) and SCC (well differentiated) were detected equally well by this technology (eFig 1 and eTable I). Using an IHC assay for detection of activated GB119, 11 it was possible to ascertain microscopic resolution of the location of activated probe, protease expression, and cancerous cells showing that they colocalized at almost all locations (Figs 2, 4, e3, e5, e6, and e8 ). Comparing probe activation and pathological findings using en face sections at different depths below the application surface revealed that the perimeter of the 2D fluorescence image reproducibly outlined the location of cancer at all depths assessed. Taken together, these data demonstrate that GB119/cathepsin-dependent fluorescent images of NMSC excisions discriminate cancerous tissue from normal-appearing skin defining the peripheral margins of BCC/SCC lesions and are not significantly affected by light scatter or diffusion by the tissue. Although previous efforts to enhance the detection and removal of skin cancer have resulted in the development of several optical fluorescence techniques, [23] [24] [25] these approaches rely both on systemic and local administration of the imaging agents or imaging using endogenous differences in contrast. However, none of these methods have yet been clinically approved in the United States. For example, skin cancers investigators attempted to use autofluorescence of skin cancer lesions, 26 photodynamic diagnosis, 27, 28 or the use of a nearinfrared fluorescent-labeled skin cancer targeted antibody, panitumumab-IRDye800. 29 Each of these approaches, however, has drawbacks, resulting in lower sensitivity and specificity, longer times (6 hours) for lesion discrimination, or the need for systemic injection with the potential of immunogenic response. Further, the systemically administered agents require costly phase-I to -III clinical trials to move toward clinical use. This approach using topical application of imaging probes to detect cancer-associated enzymes 10, 30 is the only example to show ex vivo topical application of imaging probes to excised samples can rapidly visualize tumor margins during surgical procedures. Our previous studies demonstrated the feasibility of this approach using a brain tumor model 10 and now we use this technology to demonstrate for the first time to our knowledge its potential to impact conventional skin cancer resections in human beings. We are currently conducting an institutional review boardeapproved trial to examine the specificity and sensitivity of this approach in the setting of such conventional wide local excisions. Ultimately, we envision this technology to inform the surgeon of margin status within 15 minutes of a conventional excision. This may enable surgeons to use minimal margins (eg, 3-mm vs up to 5-mm margins used for nonmorpheaform BCCs) while obtaining similar or possibly more favorable recurrence rates. Commercialization of such a product would need to be economically viable to enable community practitioners to adopt this technology. Finally, we envision that this technology could improve health care access for superior margin control for those ineligible for MMS for a variety of reasons; but QABP would not provide significant improvement as an additional step in modern MMS workflows.
In agreement with previous studies, 10, 11, 25, 31 the data show close correlation between probe activation and the presence of cancer and areas of inflammation, which contain macrophages, activate GB119, and are presumably an important source of activated cathepsins. Areas of strong accumulation of macrophages (eFig 5, B, region 4) at the cancer lesion/normal tissue interface stained with both anticathepsin-L and for activated probe. Also GB119 activation occurs in the extracellular milieu of cancer cells, a likely result of the fact that cathepsins can be secreted from the cells. Because cathepsin-B (eFig 6) expression is also associated with GB119 activation, it seems likely that Cy5-fluorescence imaging depends not only on presence of cathepsin-L but rather represents GB119/multicathepsin-dependent fluorescence from the top to bottom of the skin samples. These studies demonstrate that overexpression of cathepsin proteases is prevalent in both BCC and SCC lesions, making cathepsins an excellent biomarker for skin cancer margin detection.
The study also addressed potential limitations to this approach. A particular concern is the effect of surgery, tissue thickness, and tissue structures on the ability to visualize probe fluorescence. The presence of activated probe was detected in SCC zones but not in the cancer cell-free zones at the depth ;1.9 mm (eFig 4, B, and eFig 5, B) and correlated to the deepest cancer in the specimens that were collected: 2.5 mm (eFig 3). These depths of detection are well suited to detect cancer in the peripheral margins of the cancer indicating low impact, if any, of scattering or absorption of near-infrared light for imaging quality. In this study, we observed no difference in detection signal for the 4 subtypes of BCC and 2 subtypes of SCC examined (eFig 1). It will be critical to determine if this pattern is observed for other subtypes of BCC and SCC and to ensure that benign fibrosis/scarring in the absence of cancerous cells in addition to benign growths, eg: do trichoepitheliomas produce a QABP signal similar to tumor?
Bleeding that might occur during sample preparation could cause another potential limitation to the technique (eFig 7). Depending on the location, clot attenuation may compromise the ability to assess surgical margins ex vivo. However, blood clots in these samples were likely a result of the transport time to the research laboratory: 90 to 120 minutes. Further development of imaging protocols will involve the use of only fresh-excised specimens imaged within 10 minutes of resection using a portable imaging device, making them virtually free from clots and addressing other practical limitations of the approach presented here. eFig 1. Probe fold-activation by histopathological diagnosis. GB119/cathepsin-dependent Cy5-fluorescent signal was normalized to imaging area and fold-activation was calculated by dividing the signal from activated probe (5 minutes after treatment) by signal from nontreated (0 minutes) samples. Fold-activation is displayed by histopathological diagnosis using box plots. The bottom and top of each box, respectively, represent the 25th and 75th percentiles, and the lines outside the box extend to the minimum and maximum value. The horizontal line inside the box and the diamond represent the sample median and mean, respectively. Statistical analysis was performed only on data from subtypes that were derived from 4 or more samples. In a 1-way analysis of variance comparing means of log-transformed fold-activations among histologic diagnoses with Tukey adjustment for multiple comparisons, activation was significantly lower in normal-appearing skin compared with all histologic subtypes (adjusted P values #.01), whereas there were no statistically significant differences among any histologic diagnostic groups. BCC, Basal cell carcinoma; SCC, squamous cell carcinoma. eFig 2. Immunohistochemistry (IHC ) controls for detection of probe activation and cathepsin (CTS )-L ( green) expression in basal cell carcinoma (BCC)-containing human skin tissue. Breadloaf sections of the human skin tissue treated with GB119 (Control-1 column) or dimethylsulfoxide as a solvent alone (Control-2 column) and used to assess the specificity of anti-Cy5 and anti-CTS-L antibodies to their target molecules. Control-1 column represents IHC staining of the BCC slides adjacent to hematoxylin-eosin (H&E ) slide without primary antibodies. No signal for either CTS-L or activated GB119 was detectable. Inclusion of the primary antibody drastically increases signal (eFig 6, B, and Fig 2, B) . Control-2 column represents IHC staining of the skin tissue not pretreated with GB119, ie, it was Cy5-free, but both primary anti-Cy5 and anti-CTS-L antibody and secondary antibodies were included. CTS-L is expressed as a zymogen and expression may not correlate with its activity. Increased levels of CTS-L expression were detected at the edge of BCC ''nests'' (white arrows) and interface (white arrowheads) (Control-2), because of inclusion of the primary antibody against CTS-L. However, anti-Cy5 antibody was highly specific to its target molecule and never stained BCC nests in the GB119-free samples, which were pretreated only with solvent (Control-2). H&E and IHC scale bars = 100 m. Nuclei, 49,6-diamidino-2-phenylindole (DAPI ) (blue); Cy5, as a part of the probe ( red ). One of 10 BCC (control-1) and 1 of 4 (Control-2) representative samples is shown. Breadloaf and en face frozen sections (histology and hematoxylineosin) were used for specimens 1-55 and 56-64, respectively. Samples 1-55 were used to assess both sensitivity and specificity of the method. BCC, Basal cell carcinoma; I, infiltrative; MD, mildly differentiated; MN, micronodular; N, nodular; S, superficial; SCC, squamous cell carcinoma; WD, well differentiated. *Represented as a minimum and maximum distance between dermal and epidermal edges of the skin tissue on hematoxylineosin histology slide for each sample. y Represents GB119/cathepsin-dependent Cy5-fluorescent signal that was normalized to imaging area. Fold-activation was calculated by dividing the signal from activated probe (5 minutes after treatment) by signal from nontreated (0 minutes) samples.
